BIOMARIN PHARMACEUTICAL INC
BMRN · XNASCIK 1048477fmd_0924GAFB3122A5P5DWXYTN73Q2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 72 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1,117 | 1,314 | 1,491 | 1,704 | 1,860 | 1,846 | 2,096 | 2,419 | 2,854 | 3,221 |
| Cost of revenue | 210 | 242 | 315 | 359 | 524 | 471 | 503 | 532 | 580 | 717 |
| Gross profit | 907 | 1,072 | 1,176 | 1,345 | 1,336 | 1,376 | 1,593 | 1,887 | 2,274 | 2,504 |
| Research and development | 662 | 611 | 696 | 715 | 628 | 629 | 650 | 747 | 747 | 922 |
| Selling, general and administrative | 477 | 554 | 604 | 681 | 738 | 759 | 823 | 892 | 1,009 | 1,153 |
| Operating income | (803) | (15) | (124) | (100) | (43) | (82) | 161 | 186 | 484 | 409 |
| Interest expense | 39 | 43 | 44 | 23 | 29 | 15 | 16 | 17 | 13 | 11 |
| Interest and investment income | 7 | 15 | 23 | 23 | 17 | 10 | 18 | 58 | 75 | 75 |
| Income before taxes | (831) | (36) | (143) | (95) | (49) | (75) | 150 | 189 | 542 | 482 |
| Income tax expense | (201) | 81 | (65) | (71) | (903) | (11) | 8 | 21 | 115 | 134 |
| Net income from continuing operations | (630) | (117) | (77) | (24) | 854 | (64) | 142 | 168 | 427 | 349 |
| Net income | (630) | (117) | (77) | (24) | 854 | (64) | 142 | 168 | 427 | 349 |
| Net income to common shareholders | (630) | (117) | (77) | (24) | 854 | (64) | 142 | 168 | 427 | 349 |